Loading clinical trials...

Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin | Clinical Trials | Clareo Health

COMPLETED

Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin

A Prospective, Non-interventional Study to Collect Subject and Physician Satisfaction During Long Term Treatment of Glabellar Lines With Dysport® in Subjects of Chinese Origin in Real Clinical Practice

NCT05089357•Galderma R&D

View on ClinicalTrials.gov

Summary

This is a prospective, longitudinal, non-interventional, multi-center study to collect subject and physician satisfaction, and treatment experience with Dysport in real clinical practice in subjects of Chinese origin.

Detailed Description

Approximately 250 subjects are planned to be included in the study.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult male or female up to 65 years of age, and of Chinese origin.
•Moderate (grade 2) or severe (grade 3) glabellar lines at max frown.
•Prior to and independent of study, subject is seeking long term treatment of their glabellar lines.
•Prior to and independent of the study participation, physician intended to treat the subject with Dysport.
•Time and ability to complete the study and comply with instructions.
•Understands the study requirements and signed the informed consent form (ICF)

Exclusion Criteria

•Hypersensitive to Dysport or its excipients.
•Presence of contraindications to Dysport treatment as specified in the approved leaflet in China.
•Subject is at risk for precautions, warnings, and/or contraindications to Dysport as specified in the approved leaflet in China.

Locations (1)

Hangzhou Yanshuyuerong medical cosmetology clinic

Hangzhou, Zhejiang, China

Key Dates

Start Date

November 11, 2021

Primary Completion Date

September 12, 2023

Completion Date

December 24, 2023

Last Updated

July 9, 2025

Enrollment

250

ACTUAL participants

Conditions

Glabellar Lines

Interventions

AbobotulinumtoxinA

BIOLOGICAL

A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

NCT06481475

Moderate to Severe Glabellar Lines

View study

ACTIVE_NOT_RECRUITINGPHASE2

A Study to Evaluate AI-09 In Participants With Glabellar Lines

NCT07321834

Glabellar Lines

View study

ACTIVE_NOT_RECRUITINGPHASE3

A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 9, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin

Inclusion Criteria

Exclusion Criteria

A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

A Study to Evaluate AI-09 In Participants With Glabellar Lines

A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines

AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines